Original Research Article
Year: 2021 | Month: July-September | Volume: 6 | Issue: 3 | Pages: 1-6
DOI: https://doi.org/10.52403/gijhsr.20210701
Role of Serum Alkaline Phosphatase Levels as an Early Marker of Disease Progression in Chronic Kidney Disease
Jyothi A Natikar1, Asha G2, Alapaty Shailaja3
1,2Assistant Professor, 3Professor,
Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Center, Bangalore, Karnataka, India.
Corresponding Author: Jyothi A Natikar
ABSTRACT
Introduction: Chronic kidney disease (CKD) is an emerging condition with increasing morbidity and mortality. In chronic kidney disease (CKD), disturbance of several metabolic regulatory mechanisms cause premature ageing, accelerated cardiovascular disease (CVD), and mortality. CKD is associated with disturbances in alkaline phosphatase levels significantly in stage 4 and 5. Serum ALP levels has been shown to have a promoting effect on vascular calcification which leads to atherosclerosis and cardiovascular complication.
Aims and Objectives: To estimate the serum ALP levels and to correlate its association with CKD patients Material & methods: 50 cases of CKD and 50 controls were included in the study. Serum Urea, creatinine, alkaline phosphatase were measured in both cases and controls. Statistically significant increases in levels of all parameters were seen. The levels of alkaline phosphatase were also increased in cases but it was not statistically significant.
Conclusion: Elevated ALP levels are associated with an increased risk of End Stage Renal Disease and all-cause mortality in patients with CKD. Alkaline phosphatase levels can be used as an alternate marker for early identification of complications in CKD.
Keywords: CKD-Chronic kidney disease, ALP-Alkaline phosphatase, ESRD-End stage renal disease